Ultrafiltration is essential in peritoneal dialysis (PD) for maintenance of euvolemia, making ultrafiltration insufficiency preferably called ultrafiltration failure—an important complication. The mechanisms of ultrafiltration and ultrafiltration failure are more complex than generally assumed, especially after long-term treatment. Initially, ultrafiltration failure is mainly explained by a large number of perfused peritoneal microvessels, leading to a rapid decline of the crystalloid osmotic gradient, thereby decreasing aquaporin-mediated free water transport. The contribution of peritoneal interstitial tissue to ultrafiltration failure is limited during the first few years of PD, but becomes more important in long-term PD due to the development of interstitial fibrosis, which mainly consists of myofibroblasts.
The VR system – called stay•safe MyTraining VR – is designed for use in patients undergoing peritoneal dialysis, which uses the peritoneum in a person’s abdomen as the membrane through which fluid and dissolved substances are exchanged with the blood.
Acute kidney injury (AKI) is defined by a sudden loss of excretory kidney function. AKI is part of a range of conditions summarized as acute kidney diseases and disorders (AKD), in which slow deterioration of kidney function or persistent kidney dysfunction is associated with an irreversible loss of kidney cells and nephrons, which can lead to chronic kidney disease (CKD). New biomarkers to identify injury before function loss await clinical implementation. AKI and AKD are a global concern.
Interruptions to dialysis services in resource-limited settings, like India, amidst the COVID-19 pandemic has highlighted our ill-preparedness. We need alternative plans to safeguard the provision of this life-sustaining treatment and protect our vulnerable patients.
CloudCath, a medtech company based in San Francisco, has created the CloudCath system, a remote monitoring technology that provides clinicians with data on the spent dialysate fluid of at-home peritoneal dialysis patients. CloudCath is incorporated into the drain line of peritoneal dialysis systems, and wirelessly transmits data to the cloud, with proprietary algorithms then highlighting issues, such as infection, to clinicians.
Globally, 1 in 10 people have been diagnosed with chronic kidney disease and the number of people with advanced kidney disease is rising, but there are still over 2.5 million people that do not have access to lifesaving treatments. Why is this, and what can be done to help ensure everyone has equal access to lifesaving treatments such as dialysis?
The push to have more patients dialyzed in the home setting is gaining momentum in the United States (US) under programs like the ETC (ESRD Treatment Choices), in which some nephrology practices were mandatorily enrolled in 2021. The ETC is specifically designed to incentivise nephrologists to increase the number of patients utilizing home dialysis and increase the number of patients on the kidney transplant waiting list.
Fresenius Medical Care, a global leader in dialysis treatment, has taken another step in moving dialysis from clinical settings to the home. Fresenius introduced the Kinexus Therapy Management Platform for home dialysis, which connects clinicians to patients and helps create more personalized care. The cloud-based system supports management of peritoneal dialysis on the Liberty Select cycler and is designed to improve workflows, productivity and patient outcomes.
Silk fibroin has been widely used as fundamental components for the construction of biocompatible flexible electronics, particularly for wearable and implantable devices. Furthermore, in recent years, more attention has been paid to the investigation of the functional characteristics of silk fibroin, such as the dielectric properties, piezoelectric properties, strong ability to lose electrons, and sensitivity to environmental variables. Here, this paper not only reviews the preparation technologies for various forms of silk fibroin and the recent progress in the use of silk fibroin as a fundamental material but also focuses on the recent advanced works in which silk fibroin serves as functional components. Additionally, the challenges and future development of silk fibroin-based flexible electronics are summarized.
Sudden cardiac death (SCD) represents a major cause of death in end-stage kidney disease (ESKD). The precise estimate of its incidence is difficult to establish because studies on the incidence of SCD in ESKD are often combined with those related to sudden cardiac arrest (SCA) occurring during a haemodialysis (HD) session. The aim of the European Dialysis Working Group of ERA-EDTA was to critically review the current literature examining the causes of extradialysis SCD and intradialysis SCA in ESKD patients and potential management strategies to reduce the incidence of such events. Extradialysis SCD and intradialysis SCA represent different clinical situations and should be kept distinct.
“I think there’s a need for increased nursing support to these patients,” continued Prof Mellotte, who noted there were “relatively few” nurses assigned to home therapy provision. “We need pre-dialysis nurses [and] we need home therapy care nurses to provide that support to these patients. That is one of the barriers and we have been talking to the HSE about increasing the supports to these patients. Because most people will agree it is a better quality-of-life if you can do it, but you need training.”
A new analysis reveals that individuals with kidney failure have faced especially high hospitalization and death rates during the COVID-19 pandemic. The findings, which appear in an upcoming issue of JASN, support prioritization of these patients in COVID-19 vaccination programs.
Like most of our organs, our kidneys play an important role in the overall functioning of our body. These two bean-shaped organs sit directly below the rib cage, one on each side of the spine. Their primary job is to remove waste and fluid from the body, says , but they also maintain blood pressure and mineral levels, keep our bones strong, and help make red blood cells.
DaVita’s home care strategy has also led it to work with the provider’s largest dialysis competitor—Fresenius Medical Care—for the home-based hemodialysis machines that it picked up through its $1.9 billion acquisition of NxStage Medical. (Baxter)
The COVID-19 pandemic has and continues to have a profound impact on society and our everyday lives. As of March 2021, more than 2.5 million people around the world have died as result of the pandemic. Patients with kidney failure, particularly those receiving chronic dialysis treatment are at an increased risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulting in higher morbidity and mortality within this vulnerable population. Similarly, a recently published study highlighting the impact of COVID-19 on the dialysis population from Canada’s most populous province, Ontario, showed that patients with kidney failure receiving hemodialysis were five times more likely to be infected compared to the general population.
Home dialysis, which includes both peritoneal dialysis and home hemodialysis, allows patients to receive their dialysis treatments at home, gives patients independence and flexibility with their treatment schedules, and is associated with similar or better outcomes and lower costs compared with conventional in-center hemodialysis. Home dialysis modalities are the fastest growing types of dialysis treatments in the United States, and this trend is likely to continue as recent policies provide incentives to dialysis providers and kidney specialists to promote home dialysis.
Baxter has received an FDA clearance for its latest, portable dialysis machine designed to connect directly with electronic medical records for patients’ prescriptions and treatment data. The company’s AK 98 hemodialysis machine is not designed for home use or self-care, but to assist healthcare providers with the logistics of administering multiple treatment sessions per day with the same unit.
A clinical evaluation, ideally a month before the start of Ramadan, is necessary to assess whether patients with chronic kidney disease (CKD) can safely abstain from food and drink from dawn to dusk, particularly in temperate regions where Ramadan spans summer months and the fasting period can be up 20 hours, the authors note. Their paper, published in the Clinical Kidney Journal, details best practices for managing these patients.
TX is the most cost-effective RRT modality, followed in order by PD and HD. The strategy with an increased proportion of incident patients on PD and TX is cost-effective compared with the current practice pattern at the given WTP threshold. The planning for RRT service delivery should incorporate efforts to increase the utilisation of PD and TX in China.
The increasing prevalence of various chronic diseases such as diabetes that results in kidney disorders is a key factor aiding in expansion of the global end stage renal disease market during the forecast period between 2020 to 2030. Elements prompting this infection are diabetes, hypertension, smoking, and mature age. Diabetes is the most widely recognized reason, trailed by (hypertension). To remain alive and treat the ESRD, a patient needs to embrace dialysis or relocate their kidneys. The components fuelling the development of this market are expanding number of kidney patients, a lot of interest in the R&D, presentation of mechanically progressed supplies, for example, counterfeit kidney and low upkeep dialysis hardware.
Mobile health is the health care use of mobile devices, such as smartphones. Mobile health readiness is a prerequisite to successful implementation of mobile health programs. The aim of this study was to examine the status and correlates of mobile health readiness among individuals on dialysis.
A new California law aims to curb what sponsors say is profiteering by dialysis centers. But are there any easy answers?
Quanta Dialysis Technologies is bringing its small, lightweight blood purification system to the U.S., following its commercial launch in the U.K. last year and clinical pilots with the country’s National Health Service. With a new FDA clearance in hand, the British company plans to roll out its portable SC+ hemodialysis machine to a variety of care settings on the other side of the pond. Its modular, cartridge-based design can provide both high-flow modes—for the typical three-times-a-week appointments—or sustained, low-efficiency dialysis treatments for a gentler option.
Small enough to fit on top of a cart or desk, it can be used by healthcare professionals in hospitals as well as moved around skilled nursing facilities, with future water purification add-ons that will allow it to operate without a centralized water system.
Seventy-six of the nephrology trainees completed the survey. The researchers found that regarding the principles of PD, most respondents were moderately confident. However, only 3 and 11 percent had initiated patients on urgent-start PD and observed a PD catheter insertion, respectively. For HHD, the level of confidence was low. Most trainees attended a home dialysis continuity clinic with faculty mentorship.
PD is a safe way of renal replacement therapy to protect patients from COVID‐19 pandemic. The data obtained support that PD is successful and safe during the pandemic. Also, RM‐APD may be a better choice in patients with PD because bone mineral metabolism seems to remain more stable. Moreover, evaluating depression and anxiety at the phone visits may be important for the accurate clinical assessment.
The Homechoice Claria system was cleared for both adults and children. Its interface is available in 38 languages and features step-by-step, voice-activated instructions through an accompanying app to help guide the user through therapy.
PD differs from other dialysis options in that it uses the body’s own abdominal lining (the peritoneum) to clean the blood rather than a synthetic filter (dialyzer). If you choose PD, you’ll need a PD catheter surgically placed, typically through your abdomen. Typically the catheter exit site is allowed to heal for a few weeks, before you begin PD treatments.
Unusually high demand for dialysis to treat acute kidney injury (AKI) in patients hospitalized with COVID-19 led to rapid adoption of acute peritoneal dialysis (PD) programs at some institutions in New York City, according to reports presented at the American Society of Nephrology’s Kidney Week 2020 Reimagined virtual conference.
Fresenius Medical Care North America's (FMCNA) Renal Therapies Group announced today that DELFLEX® peritoneal dialysis solutions in Biofine®, an innovative bag material, has been approved by the U.S. Food and Drug Administration (FDA). The milestone marks another important step in the company's commitment to grow home dialysis through new and improved products.